Pharmaceuticals

Sanofi

Sanofi Rare Disease Therapy Efdoralprin Alfa Shows Superiority Over Standard of Care in Trial Results

Sanofi Requests Withdrawal of Diabetes Drug from FDA Priority Review Vouchers Program

Sanofi Issued 1 Billion Euro 3% Bond

Sanofi issued 650 million euros of medium-term notes

Sanofi Invests $294 Million in Expanding Toronto AI Center of Excellence

Morgan Stanley downgrades Sanofi's rating to neutral

Sanofi prices 2.3 billion euros bond issuance

Sanofi Announces Lower Side Effects in Nuvaxovid Phase 4 Data Compared to Moderna

Sanofi Prices €2.3 Billion Bond Offering

Sanofi Reports Q1 Sales Above Expectations and Reaffirms High-Single-Digit Growth Guidance for 2026

Swiss bank analyst maintains hold rating on Sanofi

Sanofi's Multiple Sclerosis Drug Cenrifki Receives Positive CHMP Recommendation

Sanofi released FY2026 Q4 earnings on April 23, 2026 (EST), forecast revenue USD 14.07 B, forecast EPS USD 0.1917, actual values unavailable

Sanofi released FY2026 Q1 earnings on April 23 (EST), actual revenue USD 12.89 B (forecast USD 11.72 B), actual EPS USD 0.7679 (forecast USD 0.4598)

Sanofi Reports Q1 Operating Net Income Rise, Dupixent Sales Soar

Sanofi CFO says Middle East crisis to have mild impact on 2026 sales growth

Sanofi Plans to Launch Approved Products in Europe

Sanofi Exceeds Earnings Per Share Expectations in Q1

FDA Delays Decision on Sanofi's Subcutaneous Sarclisa for Up to Three Months

FDA Approves Tzield for Children Aged 1 and Older to Delay Progression from Type 2 to Type 3 Diabetes

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

LABU

SBIO

Sanofi has provided information regarding its total number of voting rights and shares as of April 30, 2026. The company has issued 1,212,212,936 shares, with 1,329,027,146 real voting rights (excluding treasury shares) and a theoretical total of 1,346,241,660 voting rights (including treasury shares). This information complies with French commercial regulations.

GlobeNewswire

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

ALPS Medical Breakthrough

VG Health

iShares Global Healthcare

iShares Biotechnology ETF

Sanofi: Information concerning the total number of voting rights and shares - April 2026

02268

WXXWY

02269

ARKG

IBBQ

Earendil Labs has announced the successful dosing of the first cohort in a Phase I clinical trial for HXN-1011, a novel biparatopic antibody targeting Thymic Stromal Lymphopoietin (TSLP). This antibody shows high affinity and blocks TSLP receptor interactions, demonstrating potent activity in preclinical studies. The company aims to develop innovative treatments for various immunological disorders, emphasizing their commitment to advancing next-generation biologics therapies.

prnewswire

WUXI XDC

WuXi Biologics

WUXI BIO

iShares US Pharma

China Southern Hang Seng Biotech ETF(QDII)

Ark Genomic Revolution ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

First Trust NYSE Arca Biotech Index Fd

E Fund CSI 300 Health Care ETF

Huaan Hang Seng Biotech ETF

Invesco Nasdaq Biotechnology ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

Penghua CSI HK Connect Health Care Composite ETF

Tianhong CNI BIOMEDICINE ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Bosera Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng Health Care ETF(QDII)

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

Guotai CSI Bio-medicine ETF

07:00 ETEarendil Labs Announces First Cohort Dosed in Phase I Study of Novel Biparatopic Antibody Targeting Thymic Stromal Lymphopoietin (TSLP)

REPL

BCAX

Bicara Therapeutics has appointed Chris Sarchi as its chief commercial officer as it prepares for a potential accelerated approval of its cancer drug next year. Sarchi, previously at Replimune and Sanofi, joins at a crucial time following significant layoffs after an FDA rejection of a melanoma drug. Bicara aims to leverage a $362 million IPO to support trials for its lead asset, ficerafusp alfa, currently in a pivotal trial for head and neck cancer. Sarchi's role will be pivotal in transitioning Bicara into a commercial biotech.

Fiercepharma

Replimune

Bicara Therapeutics

Bicara Therapeutics hires Replimune, Sanofi alum as CCO

Doceree has launched Daily Command, an AI-powered operating system for healthcare marketing, co-built by 75 senior leaders from top agencies like Sanofi and Merck. This product aims to transform how pharmaceutical brand teams plan, execute, and measure their work, integrating agency strategies directly into the brand team's daily operations. The launch is set for July 14, 2026, and emphasizes a shift in agency value perception, as agencies whose work is visible in Daily Command are likely to retain accounts amid budget pressures. The platform allows agencies to integrate their proprietary tools, ensuring they maintain their competitive edge.

Fidelity

Merck

Bristol Myers Squibb

Eli Lilly

Omnicom

Bristol-Myers Squibb Company

The Agencies Building Pharma's Next Decade Just Picked Their Software: Daily Command Launches With 18 of the Industry's Most Senior Agency Leaders Already Inside It

SNYNF

75 senior leaders from the pharmaceutical industry announced a new operating model for pharma marketing at the Doceree Makers Summit. They declared the end of the fragmented software stack that has dominated the industry for two decades and introduced Daily Command, a unified system designed to streamline workflows for brand teams. This coordinated effort, involving major companies like Sanofi and Merck, aims to replace the existing tools with a single product that enhances efficiency and decision-making in pharma marketing. Daily Command will officially launch on May 7, 2026, with a closed beta starting in June.

17:15 ET75 of Pharma's Most Senior Marketers Just Walked Away From a $12 Billion Tool Stack

Sanofi(SNY.US)

Sanofi: Information concerning the total number of voting rights and shares - April 2026

07:00 ETEarendil Labs Announces First Cohort Dosed in Phase I Study of Novel Biparatopic Antibody Targeting Thymic Stromal Lymphopoietin (TSLP)

Bicara Therapeutics hires Replimune, Sanofi alum as CCO

The Agencies Building Pharma's Next Decade Just Picked Their Software: Daily Command Launches With 18 of the Industry's Most Senior Agency Leaders Already Inside It

17:15 ET75 of Pharma's Most Senior Marketers Just Walked Away From a $12 Billion Tool Stack